Andersson, H.; Sobti, A.; Jimenez, D.G.; de Coaña, Y.P.; Ambarkhane, S.V.; Hägerbrand, K.; Smith, K.E.; Lindstedt, M.; Ellmark, P.
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody. Cells 2023, 12, 2365.
https://doi.org/10.3390/cells12192365
AMA Style
Andersson H, Sobti A, Jimenez DG, de Coaña YP, Ambarkhane SV, Hägerbrand K, Smith KE, Lindstedt M, Ellmark P.
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody. Cells. 2023; 12(19):2365.
https://doi.org/10.3390/cells12192365
Chicago/Turabian Style
Andersson, Hampus, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt, and Peter Ellmark.
2023. "Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody" Cells 12, no. 19: 2365.
https://doi.org/10.3390/cells12192365
APA Style
Andersson, H., Sobti, A., Jimenez, D. G., de Coaña, Y. P., Ambarkhane, S. V., Hägerbrand, K., Smith, K. E., Lindstedt, M., & Ellmark, P.
(2023). Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody. Cells, 12(19), 2365.
https://doi.org/10.3390/cells12192365
